U.S. Hereditary Genetic Testing Market: Focus on Product, Sample Type, Application Area, and Genetic Testing Type – Analysis and Forecast, 2022-2032

$5,250$8,100

The U.S. hereditary genetic testing market was valued at $7.57 billion in 2021 and is expected to grow with a CAGR of 13.09% and reach $29.28 billion by 2032.

SKU: BHP1290SA Category: Tag:

Description

U.S. Hereditary Genetic Testing Market Overview

The U.S. hereditary genetic testing market was valued at $7.57 billion in 2021 and is expected to grow with a CAGR of 13.09% and reach $29.28 billion by 2032. The growth in the U.S. hereditary genetic testing market is expected to be driven by growing demand for early and preventive care and increasing prevalence and associated disease burden related to various cancer, among others.

Market Lifecycle Stage

The U.S. hereditary genetic testing market appears to be highly dynamic at the moment, with companies focusing on the adoption of advanced technologies in order to cater to the demand of processing large data as well as efforts to make genetic testing reach a larger population.

Market Segmentation

Segment 1: by Product

1. Services
2. Kits
3. Consumables
4. Others

Among the product segment, the services segment in the U.S. hereditary genetic testing market occupies the largest share of the market and is expected to dominate in the coming years as well. This is because companies are actively providing services to hereditary testing laboratories in addition to providing genetic testing kits and consumables.

Segment 2: by Sample

1. Blood
2. Saliva
3. Tumor Tissue
4. Bone Marrow
5. Other Sample Types

Among the sample segment, blood samples are majorly used for conducting hereditary genetic testing in the U.S.

Segment 3: by Application Area

1. Clinical Diagnostics
2. Academics and Research
3. Drug Discovery
4. Monitoring and Screening

Among application area, all the four sub-segments constitute an almost equal share in the U.S. hereditary genetic testing market. However, drug discovery currently occupies a relatively major share, and the share of academics and research is expected to increase in the coming years.

Recent Developments in the U.S. Hereditary Genetic Testing Market

• On 3 October 2022, Laboratory Corporation of America Holdings concluded the transactions, establishing a long-term laboratory connection with Ascension. This partnership with Ascension boosts access to Laboratory Corporation of America Holdings’ clinical laboratory services, analytics, and laboratory network for the Ascension-served communities, eventually enhancing productivity and healthcare services.
• On 29 September 2022, Illumina, Inc. announced the launch of the NovaSeq X Series (NovaSeq X and NovaSeq X Plus), the new production-scale sequencers. These production-scale sequencers are designed to enable faster, more powerful, and more sustainable sequencing. With the aid of this technology, the company aims to lead advancing genomic research and clinical understanding, ultimately improving patient lives.
• On 14 September 2022, Qiagen, N.V. entered into a partnership with Neuron23 in order to provide a companion diagnosis for Neuron23’s brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor for Parkinson’s disease.

Demand Drivers and Restraints

Following are the demand drivers identified for the U.S. hereditary genetic testing market

• Growing Demand for Early and Preventive Care
• Increasing Number of New Cases of Cancer Indications and Associated Disease Burden
• Increasing Technological Advancement Resulting in Improved Outcome
• Rising Prevalence of Genetic Disorders

The U.S. hereditary genetic testing market is expected to face some challenges due to the following reasons

• Hesitation Among Patients Toward Genetic Testing
• High Capital Requirement Hampering the Expansion
• Lack of Accurate Risk Assessment in Neuromuscular Disorders

How can this report add value to an organization?

Product/Innovation Strategy: The report highlights the approaches being considered for making the test reach a larger population. The companies are incorporating data analytics and various software applications that can help them in fetching a more accurate result from a large genome data bank available to the company. The report also provides an epidemiology forecast of selected cancer indications across different regions of the U.S., which again helps in assessing the expected market opportunity for hereditary genetic testing.

Growth/Marketing Strategy: The several growth strategies identified in the report include increased focus toward technological advancement in making the tests more accurate as well as quick, making the tests more accessible to a broader population either by reducing the price or by getting them approved for reimbursement.

Competitive Strategy: The report provides insight into the existing competition in the U.S. hereditary genetic testing market. The leading players, along with their contributions and market shares, have been identified and profiled in the report. Moreover, a detailed competitive benchmarking of the players operating in the U.S. hereditary genetic testing market has been included to help the reader understand how players stand against each other, presenting a clear market landscape. The report also highlights the key activities the companies were engaged in in the last three years. This will additionally help in evaluating the dynamics of the market with respect to growth and sustainability in the business.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

The U.S. hereditary genetic testing market in 2021 was dominated by the following key players with a total market share of 51.45%:

1. Laboratory Corporation of America Holdings
2. Quest Diagnostics Incorporated
3. F. Hoffmann-La Roche Ltd.

The following companies had a total market share of over 25% in 2021 and were highly active in the U.S. hereditary genetic testing market:

1. BGI
2. Illumina, Inc.
3. Eurofins Scientific SE
4. Myriad Genetics, Inc.
5. Natera, Inc.

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Base Year

2022

Base Market Size

$8.56 Billion in 2022

Currency

USD

Forecast Year

2032

Market Size Forecast

$29.28 Billion by 2032

CAGR

13.09%

Table of Contents

1 Market Definition
1.1 Inclusion and Exclusion Criteria
2 Research Scope
2.1 Target Audience
2.2 Key Questions Answered in the Report
3 Research Methodology
3.1 Primary Data Sources
3.2 Secondary Data Sources
3.3 Patient Pool Estimation
3.4 Market Estimation
3.5 Criteria for Company Profiling
4 Markets
4.1 Competitive Landscape
4.1.1 Strategic Activities
4.1.2 Mergers and Acquisitions
4.1.3 Product Launches
4.1.4 Synergistic Activities
4.1.5 Expansion
4.1.6 Market Share Analysis
4.1.7 Growth Share Analysis
5 U.S. Hereditary Genetic Testing: Overview
5.1 Current State of Hereditary Genetic Testing
5.2 Market Footprint and Future Potential
6 Market Dynamics
6.1 Overview
6.2 Impact Analysis
6.3 Market Drivers
6.3.1 Growing Demand for Early and Preventive Care
6.3.2 Increasing Number of New Cases of Cancer Indications and Associated Disease Burden
6.3.3 Increasing Technological Advancement Resulting in Improved Outcome
6.3.4 Rising Prevalence of Genetic Disorders
6.4 Market Restraints
6.4.1 Hesitation Among Patients Toward Genetic Testing
6.4.2 High Capital Requirement Hampering the Expansion
6.4.3 Lack of Accurate Risk Assessment in Neuromuscular Disorders
6.5 Market Opportunities
6.5.1 Technological Advancements for Exome Sequencing
6.5.2 Rise of Direct-to-Consumer (DTC) Testing Services
7 U.S. Hereditary Genetic Testing: Industry Analysis
7.1 Legal and Regulatory Framework
7.2 Workflow
7.3 Reimbursement Scenario
8 U.S. Hereditary Genetic Testing Market (by Product)
8.1 Overview
8.2 Kits and Consumables
8.3 Services
8.4 Others
9 U.S. Hereditary Genetic Testing Market (by Oncology Genetic Testing Type)
9.1 Overview
9.2 Breast Cancer
9.3 Colorectal Cancer
9.4 Prostate Cancer
9.5 Lung Cancer
9.6 Melanoma
9.7 Other Oncology Genetic Testing
10 U.S. Hereditary Genetic Testing Market (by Cardiology Genetic Testing Type)
10.1 Overview
10.2 Cardiomyopathy
10.3 Arrhythmia
10.4 Other Cardiology Genetic Testing
11 U.S. Hereditary Genetic Testing Market (by Neurology Genetic Testing Type)
11.1 Overview
11.2 Epilepsy
11.3 Neurodegenerative Disorder
11.4 Neuromuscular Disorder
11.5 Other Neurological Disorders
12 U.S. Hereditary Genetic Testing Market (by Other Genetic Testing Type)
12.1 Newborn Screening
12.2 Non-Invasive Prenatal (NIPT) Testing
12.3 Rare Disease Testing
12.4 Direct-to-Consumer Genetic Testing
13 U.S. Hereditary Genetic Testing Market (by Sample Type)
13.1 Overview
13.2 Saliva
13.3 Blood
13.4 Tumor Tissue
13.5 Bone Marrow
13.6 Other Sample Types
14 U.S. Hereditary Genetic Testing Market (by Application Area)
14.1 Academics and Research
14.2 Clinical Diagnostics
14.3 Drug Discovery
14.4 Monitoring and Screening
15 Competitive Benchmarking and Company Profiles
15.1 Agilent Technologies, Inc.
15.1.1 Company Overview
15.1.2 Role of Agilent Technologies, Inc. in the U.S. Hereditary Genetic Testing Market
15.1.3 Product Portfolio
15.1.4 Key Competitors of the Company
15.1.5 Financials
15.1.6 Key Insights about the Financial Health of the Company
15.1.7 Business Strategies
15.1.8 Corporate Strategies
15.1.9 Analyst’s Perspective
15.2 F Hoffmann-La Roche Ltd.
15.2.1 Company Overview
15.2.2 Role of F. Hoffmann-La Roche Ltd in the U.S. Hereditary Genetic Testing Market
15.2.3 Product Portfolio
15.2.4 Key Competitors of the Company
15.2.5 Financials
15.2.6 Key Insights about the Financial Health of the Company
15.2.7 Business Strategies
15.2.8 Corporate Strategies
15.2.9 Analyst’s Perspective
15.3 Ambry Genetics
15.3.1 Company Overview
15.3.2 Role of Ambry Genetics in the U.S. Hereditary Genetic Testing Market
15.3.3 Product Portfolio
15.3.4 Key Competitors of the Company
15.3.4.1.1 Business Strategies
15.3.5 Corporate Strategies
15.3.6 Analyst Perspective
15.4 BGI
15.4.1 Company Overview
15.4.2 Role of BGI in the U.S. Hereditary Genetic Testing Market
15.4.3 Product Portfolio
15.4.4 Key Competitors of the Company
15.4.5 Corporate Strategies
15.4.6 Analyst’s Perspective
15.5 CENTOGENE N.V.
15.5.1 Company Overview
15.5.2 Role of CENTOGENE N.V. in the U.S. Hereditary Genetic Testing Market
15.5.3 Product Portfolio
15.5.4 Key Competitors of the Company
15.5.5 Financials
15.5.6 Key Insights about the Financial Health of the Company
15.5.7 Business Strategies
15.5.8 Corporate Strategies
15.5.9 Analyst Perspective
15.6 Eurofins Scientific SE
15.6.1 Company Overview
15.6.2 Role of Eurofins Scientific SE in the U.S. Hereditary Genetic Testing Market
15.6.3 Product Portfolio
15.6.4 Key Competitors of the Company
15.6.5 Financials
15.6.6 Corporate Strategies
15.6.7 Analyst Perspective
15.7 Illumina, Inc.
15.7.1 Company Overview
15.7.2 Role of Illumina, Inc. in the U.S. Hereditary Genetic Testing Market
15.7.3 Product Portfolio
15.7.4 Key Competitors of the Company
15.7.5 Financials
15.7.6 Key Insights about the Financial Health of the Company
15.7.7 Business Strategies
15.7.8 Corporate Strategies
15.7.9 Analyst Perspective
15.8 Invitae Corporation
15.8.1 Company Overview
15.8.2 Role of Invitae Corporation in the U.S. Hereditary Genetic Testing Market
15.8.3 Product Portfolio
15.8.4 Key Competitors of the Company
15.8.5 Financials
15.8.6 Key Insights about the Financial Health of the Company
15.8.7 Business Strategies
15.8.8 Corporate Strategies
15.8.9 Analyst Perspective
15.9 Quest Diagnostics Incorporated
15.9.1 Company Overview
15.9.2 Role of Quest Diagnostics Incorporated in the U.S. Hereditary Genetic Testing Market
15.9.3 Product Portfolio
15.9.4 Key Competitors of the Company
15.9.5 Financials
15.9.6 Business Strategies
15.9.7 Corporate Strategies
15.9.8 Analyst Perspective
15.1 Thermo Fisher Scientific Inc.
15.10.1 Company Overview
15.10.2 Role of Thermo Fisher Scientific Inc. in the U.S. Hereditary Genetic Testing Market
15.10.3 Product Portfolio
15.10.4 Key Competitors of the Company
15.10.5 Financials
15.10.6 Key Insights about the Financial Health of the Company
15.10.7 Business Strategies
15.10.8 Corporate Strategies
15.10.9 Analyst Perspective
15.11 Fulgent Genetics, Inc.
15.11.1 Company Overview
15.11.2 Role of Fulgent Genetics, Inc. in the U.S. Hereditary Genetic Testing Market
15.11.3 Key Competitors of the Company
15.11.4 Financials
15.11.5 Key Insights about the Financial Health of the Company
15.11.6 Corporate Strategies
15.11.7 Analyst Perspective
15.12 Exact Sciences Corporation
15.12.1 Company Overview
15.12.2 Role of Exact Sciences Corporation in the U.S. Hereditary Genetic Testing Market
15.12.3 Key Competitors of the Company
15.12.4 Financials
15.12.5 Key Insights about the Financial Health of the Company
15.12.6 Corporate Strategies
15.12.7 Analyst Perspective
15.13 Guardant Health
15.13.1 Company Overview
15.13.2 Role of Guardant Health in the U.S. Hereditary Genetic Testing Market
15.13.3 Product Portfolio
15.13.4 Key Competitors of the Company
15.13.5 Financials
15.13.6 Key Insights about the Financial Health of the Company
15.13.7 Business Strategies
15.13.8 Corporate Strategies
15.13.9 Analyst Perspective
15.14 Laboratory Corporation of America Holdings
15.14.1 Company Overview
15.14.2 Role of Laboratory Corporation of America Holdings. in the U.S. Hereditary Genetic Testing Market
15.14.3 Key Competitors of the Company
15.14.4 Financials
15.14.5 Business Strategies
15.14.6 Corporate Strategies
15.14.7 Analyst Perspective
15.15 PerkinElmer Inc.
15.15.1 Company Overview
15.15.2 Role of PerkinElmer Inc. in the U.S. Hereditary Genetic Testing Market
15.15.3 Key Competitors of the Company
15.15.4 Financials
15.15.5 Key Insights about the Financial Health of the Company
15.15.6 Business Strategies
15.15.7 Analyst Perspective
15.16 Emerging Companies
15.16.1 Natera, Inc.
15.16.1.1 Company Overview
15.16.1.2 Role of Natera Inc. in the U.S. Hereditary Genetic Testing Market
15.16.1.3 Key Competitors of the Company
15.16.1.4 Financials
15.16.1.5 Key Insights about the Financial Health of the Company
15.16.1.6 Business Strategies
15.16.1.7 Corporate Strategies
15.16.1.8 Analyst Perspective
15.16.2 Color Health, Inc.
15.16.2.1 Company Overview
15.16.2.2 Role of Color Health, Inc. in the U.S. Hereditary Genetic Testing Market
15.16.2.3 Product Portfolio
15.16.2.4 Key Competitors of the Company
15.16.2.5 Corporate Strategies
15.16.2.6 Analyst Perspective
List of Figures
Figure 1: Share of U.S. Hereditary Genetic Testing Market (by Product), 2021 vs. 2032
Figure 2: Share of U.S. Hereditary Genetic Testing Market (by Application Area), 2021 vs. 2032
Figure 3: Impact Analysis
Figure 4: U.S. Hereditary Genetic Testing Market Segmentation
Figure 5: U.S. Hereditary Genetic Market Methodology
Figure 6: Primary Research Methodology
Figure 7: Bottom-Up Approach (Segment-Wise Analysis)
Figure 8: Share of Strategic Activities, October 2019-September 2022
Figure 9: Share of Key Players Engaged in Mergers and Acquisitions, October 2019-September 2022
Figure 10: Share of Product Launches by Leading Players, October 2019-September 2022
Figure 11: Share of Synergistic Activities by Leading Players, October 2019-September 2022
Figure 12: Number of Expansion Activities by Leading Players, October 2019-September 2022
Figure 13: Market Share Analysis for the U.S. Hereditary Genetic Testing Market, 2021
Figure 14: Growth Share Matrix for U.S. Hereditary Genetic Testing Market (by Company), 2020-2021
Figure 15: Impact Analysis
Figure 16: Number of Genetic Tests Reimbursed by Medicare in the U.S., 2016-2019
Figure 17: Number of New Cases by Different Forms of Cancer in the U.S., (2015-2021)
Figure 18: Genetic Disorder Prevalence in the U.S. (by Region), 2021-2032
Figure 19: U.S. Federal Agencies and their Role in Genetic Tests
Figure 20: U.S. FDA Regulatory Workflow for Diagnostic Tests
Figure 21: Overall Reimbursement Landscape for Genetic Testing, 2018
Figure 22: U.S. Hereditary Genetic Testing Market (by Product)
Figure 23: U.S. Hereditary Genetic Testing Market (Kits), $Billion, 2021-2032
Figure 24: U.S. Hereditary Genetic Testing Market (Consumables), $Billion, 2021-2032
Figure 25: U.S. Hereditary Genetic Testing Market (Services), $Billion, 2021-2032
Figure 26: U.S. Hereditary Genetic Testing Market (Others), $Billion, 2021-2032
Figure 27: U.S. Hereditary Genetic Testing Market (Oncology Genetic Testing Type), $Billion, 2021-2032
Figure 28: U.S. Incidence for Breast Cancer, 2021-2032
Figure 29: U.S. Hereditary Genetic Testing Market (Breast Cancer), $Billion, 2021-2032
Figure 30: U.S. Incidence for Colorectal Cancer, 2021-2032
Figure 31: U.S. Hereditary Genetic Testing Market (Colorectal Cancer), $Billion, 2021-2032
Figure 32: U.S. Incidence for Prostate Cancer, 2021-2032
Figure 33: U.S. Hereditary Genetic Testing Market (Prostate Cancer), $Billion, 2021-2032
Figure 34: U.S. Incidence for Lung Cancer, 2021-2032
Figure 35: U.S. Hereditary Genetic Testing Market (Lung Cancer), $Billion, 2021-2032
Figure 36: U.S. Incidence for Melanoma, 2021-2032
Figure 37: U.S. Hereditary Genetic Testing Market (Melanoma), $Billion, 2021-2032
Figure 38: U.S. Hereditary Genetic Testing Market (Other Oncology Genetic Testing), $Billion, 2021-2032
Figure 39: U.S. Hereditary Genetic Testing Market (Cardiology), $Billion, 2021-2032
Figure 40: U.S. Hereditary Genetic Testing Market (Cardiomyopathy), $Billion, 2021-2032
Figure 41: U.S. Hereditary Genetic Testing Market (Arrhythmia), $Billion, 2021-2032
Figure 42: U.S. Hereditary Genetic Testing Market (Other Cardiology Genetic Testing), $Billion, 2021-2032
Figure 43: U.S. Hereditary Genetic Testing Market (Neurology), $Billion, 2021-2032
Figure 44: U.S. Hereditary Genetic Testing Market (Epilepsy), $Billion, 2021-2032
Figure 45: U.S. Hereditary Genetic Testing Market (Neurodegenerative Disorder), $Billion, 2021-2032
Figure 46: U.S. Hereditary Genetic Testing Market (Neuromuscular Disorder), $Billion, 2021-2032
Figure 47: U.S. Hereditary Genetic Testing Market (Other Neurological Disorders), $Billion, 2021-2032
Figure 48: U.S. Hereditary Genetic Testing Market (Newborn Screening), $Billion, 2021-2032
Figure 49: U.S. Hereditary Genetic Testing Market (Non-Invasive Prenatal Testing), $Billion, 2021-2032
Figure 50: U.S. Hereditary Genetic Testing Market (Rare Disease Testing), $Billion, 2021-2032
Figure 51: U.S. Hereditary Genetic Testing Market (Direct-to-Consumer Testing), $Billion, 2021-2032
Figure 52: Sample Types Used in Hereditary Genetic Testing
Figure 53: U.S. Hereditary Genetic Testing Market (Saliva), $Billion, 2021-2032
Figure 54: U.S. Hereditary Genetic Testing Market (Blood), $Billion, 2021-2032
Figure 55: U.S. Hereditary Genetic Testing Market (Tumor Tissue), $Billion, 2021-2032
Figure 56: U.S. Hereditary Genetic Testing Market (Bone Marrow), $Billion, 2021-2032
Figure 57: U.S. Hereditary Genetic Testing Market (Other Sample Types) , $Billion, 2021-2032
Figure 58: U.S. Hereditary Genetic Testing Market (Academics and Research) , $Billion, 2021-2032
Figure 59: U.S. Hereditary Genetic Testing Market (Clinical Diagnostics) , $Billion, 2021-2032
Figure 60: U.S. Hereditary Genetic Testing Market (Drug Discovery), $Billion, 2021-2032
Figure 61: U.S. Hereditary Genetic Testing Market (Monitoring and Screening), $Billion, 2021-2032
Figure 62: Agilent Technologies Inc.: Product Portfolio
Figure 63: Agilent Technologies Inc.: Overall Financials, $Million, 2019-2021
Figure 64: Agilent Technologies Inc.: Net Revenue (by Region), $Million, 2019-2021
Figure 65: Agilent Technologies Inc.: Net Revenue (by Segment), $Million, 2019-2021
Figure 66: Agilent Technologies Inc.: R&D Expenditure, $Million, 2019-2021
Figure 67: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 68: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021
Figure 69: F. Hoffmann-La Roche Ltd: Net Revenue (by Region), $Million, 2019-2021
Figure 70: F. Hoffmann-La Roche Ltd: Net Revenue (by Segment), $Million, 2019-2021
Figure 71: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021
Figure 72: Ambry Genetics: Product Portfolio
Figure 73: BGI: Product Portfolio
Figure 74: CENTOGENE N.V.: Product Portfolio
Figure 75: CENTOGENE N.V.: Overall Financials, $Million, 2019-2021
Figure 76: CENTOGENE N.V.: Net Revenue (by Region), $Million, 2019-2021
Figure 77: CENTOGENE N.V.: Net Revenue (by Segment), $Million, 2019-2021
Figure 78: CENTOGENE N.V.: R&D Expenditure, $Million, 2019-2021
Figure 79: Eurofins Scientific SE: Product Portfolio
Figure 80: Eurofins Scientific SE: Overall Financials, $Million, 2019-2021
Figure 81: Eurofins Scientific SE: Net Revenue (by Region), $Million, 2019-2021
Figure 82: Illumina, Inc.: Product Portfolio
Figure 83: Illumina, Inc.: Overall Financials, $Million, 2019-2021
Figure 84: Illumina Inc.: Net Revenue (by Segment), $Million, 2019-2021
Figure 85: Illumina Inc.: R&D Expenditure, $Million, 2019-2021
Figure 86: Illumina Inc.: Products and Services, $Million, 2019-2021
Figure 87: Invitae Corporation: Product Portfolio
Figure 88: Invitae Corporation: Overall Financials, $Million, 2019-2021
Figure 89: Invitae Corporation: Net Revenue (by Region), $Million, 2019-2021
Figure 90: Invitae Corporation: R&D Expenditure, $Million, 2019-2021
Figure 91: Quest Diagnostics Incorporated: Product Portfolio
Figure 92: Quest Diagnostics Incorporated: Overall Financials, $Million, 2019-2021
Figure 93: Quest Diagnostics Incorporated: Net Revenue (by Segment), $Million, 2019-2021
Figure 94: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 95: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021
Figure 96: Thermo Fisher Scientific Inc.: Net Revenue (by Segment), $Million, 2019-2021
Figure 97: Thermo Fisher Scientific Inc.: Net Revenue (by Region), $Million, 2019-2021
Figure 98: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021
Figure 99: Fulgent Genetics, Inc.: Overall Financials, $Million, 2019-2021
Figure 100: Fulgent Genetics, Inc.: Net Revenue (by Region), $Million, 2019-2021
Figure 101: Fulgent Genetics, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 102: Exact Sciences Corporation: Overall Financials, $Million, 2019-2021
Figure 103: Exact Sciences Corporation: Net Revenue (by Segment), $Million, 2019-2021
Figure 104: Exact Sciences Corporation: Net Revenue (by Region), $Million, 2019-2021
Figure 105: Exact Sciences Corporation: R&D Expenditure, $Million, 2019-2021
Figure 106: Guardant Health: Product Portfolio
Figure 107: Guardant Health: Overall Financials, $Million, 2019-2021
Figure 108: Guardant Health: Net Revenue (by Region), $Million, 2019-2021
Figure 109: Guardant Health: R&D Expenditure, $Million, 2019-2021
Figure 110: Laboratory Corporation of America Holdings.: Overall Financials, $Million, 2019-2021
Figure 111: Laboratory Corporation of America Holdings.: Net Revenue (by Segment), $Million, 2019-2021
Figure 112: PerkinElmer Inc.: Overall Financials, $Million, 2019-2021
Figure 113: PerkinElmer Inc.: Net Revenue (by Segment), $Million, 2019-2021
Figure 114: PerkinElmer Inc.: Net Revenue (by Region), $Million, 2019-2021
Figure 115: PerkinElmer Inc.: R&D Expenditure, $Million, 2019-2021
Figure 116: Natera Inc.: Overall Financials, $Million, 2019-2021
Figure 117: Natera Inc.: R&D Expenditure, $Million, 2019-2021
Figure 118: Color Health, Inc.: Product Portfolio
List of Tables
Table 1: Product Examples and Applications in the U.S. Hereditary Genetic Testing Market
Table 2: Product Examples for Breast Cancer Genetic Testing
Table 3: Product Examples for Colorectal Cancer Genetic Testing
Table 4: Product Examples for Prostate Cancer Genetic Testing
Table 5: Product Examples for Lung Cancer Genetic Testing
Table 6: Product Examples for Melanoma Genetic Testing
Table 7: Product Examples for Other Cancer Types Genetic Testing
Table 8: Product Examples for Cardiomyopathy Genetic Testing
Table 9: Product Examples for Other Cardiology Genetic Testing
Table 10: Product Examples for Epilepsy Genetic Testing
Table 11: Product Examples for Genetic Testing of Neurodegenerative Disorder
Table 12: Product Examples for Genetic Testing of Neuromuscular Disorder
Table 13: Product Examples for Genetic Testing of Other Neurological Disorders
Table 14: Agilent Technologies Inc.: Key Competitors
Table 15: F. Hoffmann-La Roche Ltd: Key Competitors
Table 16: CENTOGENE N.V.: Key Competitors
Table 17: Eurofins Scientific SE: Key Competitors
Table 18: Illumina, Inc.: Key Competitors
Table 19: Invitae Corporation: Key Competitors
Table 20: Quest Diagnostics Incorporated: Key Competitors
Table 21: Thermo Fisher Scientific Inc.: Key Competitors
Table 22: Fulgent Genetics, Inc.: Key Competitors
Table 23: Exact Sciences Corporation: Key Competitors
Table 24: Guardant Health: Key Competitors
Table 25: Laboratory Corporation of America Holdings.: Key Competitors
Table 26: PerkinElmer Inc.: Key Competitors
Table 27: Natera Inc.: Key Competitors
Table 28: Color Health, Inc.: Key Competitors

Companies Mentioned

Agilent Technologies, Inc.
F. Hoffmann-La Roche Ltd.
Ambry Genetics
BGI
CENTOGENE N.V.
Eurofins Scientific SE
Illumina, Inc.
Invitae Corporation
Quest Diagnostics Incorporated
Thermo Fisher Scientific Inc.
Fulgent Genetics, Inc.
Exact Sciences Corporation
Guardant Health
Laboratory Corporation of America Holdings
PerkinElmer Inc.
Natera, Inc.
Color Health, Inc.

Reviews

There are no reviews yet.

Be the first to review “U.S. Hereditary Genetic Testing Market: Focus on Product, Sample Type, Application Area, and Genetic Testing Type – Analysis and Forecast, 2022-2032”

Page Contents
[class^="wpforms-"]
[class^="wpforms-"]